IngredientsChemical name and synonyms. Indole-3-carbinol (I3C), also called 3-(hydroxymethyl)indole, is a naturally occurring modulator of carcinogenesis whose biological activity is at least partially dependent on its conversion to active substances in acidic media. Its molecular formula is C9H9NO, and its CAS registry number is 700-06-1. It is an off-white powder with a melting point of 96° to 99°C. It is soluble in benzene, ethanol, and pentane, and is an unstable compound that undergoes rapid oligomerization in acid pH environments, like the stomach.
Botanical classification and natural origin. Indole-3-carbinol is a naturally formed breakdown product of glucosinolate glucobrassicin, a component found in cruciferous vegetables of the Brassica genus, including broccoli, Brussels sprouts, cauliflower, cabbage, kale, kohlrabi, and turnips. Glucobrassicin, the glucosinolate precursor of I3C, is found in a number of cruciferous vegetables, including broccoli, Brussels sprouts, cabbage, cauliflower, collard greens, kale, kohlrabi, mustard greens, radish, rutabaga, and turnip. Although glucosinolates are present in relatively high concentrations in cruciferous vegetables, glucobrassicin makes up only about 8%–12% of the total glucosinolates. Brussels sprouts, for example, contain 1.6–2.7 mg/g dry weight glucobrassicin.
Biosynthetic origin. Among the glucosinolates, glucobrassicin (3-indolylmethyl glucosinolate) is the predominant indolic component, which can be converted into indole-3-carbinol (I3C) when hydrolyzed by the enzyme myrosinase. Glucobrassicin is an indole glucosinolate derived from tryptophan; under neutral pH conditions, it is metabolized to indole-3-carbinol via unstable indole-3-ylmethyl-isothiocyanate intermediates. These compounds occur as glucosinolate conjugates in cruciferous vegetables and are released when one chews or otherwise macerates the vegetable.
Physical and chemical instability. Indole-3-carbinol is an unstable compound that undergoes rapid oligomerization in acid pH environments, like the stomach. At low pH, a wide variety of condensation products are formed, ranging from linear and cyclic dimers, trimers, and tetramers to extended heterocyclic compounds such as indolocarbazoles. The primary condensation products produced in vivo include DIM (3,3′-diindolylmethane), ICZ (indolo[3,2-b]-carbazole), LTr1 (a linear trimer), CTr (a cyclic trimer), and CTet (a cyclic tetramer).
Common forms and preparations. Indole-3-carbinol is sold as a sole ingredient in dietary supplements or as a combination nutraceutical along with a variety of herbs and/or vitamins. It is marketed for its potential ability to prevent cancer and provide other health benefits, such as detoxifying the liver and boosting the immune system. Supplemental forms are typically encapsulated powders. Indole-3-carbinol has most often been used by adults at a dose of 200 mg by mouth twice daily for up to 5 years in the clinical research context, though other doses have also been studied (see Dosage section).
Indole-3-carbinol as an isolated or characterized phytochemical has no distinct pre-modern traditional use as a defined medicinal substance; however, the foods that contain its precursors have a long history in human nutrition and folk medicine across multiple cultures.
It was in the 20th century that epidemiological studies pointing to the protective properties of cruciferous vegetables in cancer-protecting diets began to accumulate. A meta-analysis of studies carried out over 18 years in Europe revealed an inverse association between weekly consumption of cruciferous vegetables and several common cancers, including colorectal, breast, kidney, and upper digestive tract cancers.
Natural products from vegetable sources have been widely used in traditional medicine as preparations for treatment of a variety of human ailments, and phytochemicals and their derivatives have long formed an empirical basis for ethnobotanical practices. Brassica vegetables — cabbage, kale, turnips, and mustard greens — figure prominently in the traditional dietary practices of European, East Asian, and Indian culinary cultures, where fermented and cooked preparations (such as sauerkraut and kimchi) provided regular exposure to glucosinolate-containing foods. The science of isolating and characterizing I3C as the specific bioactive constituent released from these vegetables, however, is a development of late-20th-century phytochemistry and cancer biology.
Lee W. Wattenberg, who spent his entire career at the University of Minnesota, was a true pioneer in the field of chemoprevention. His groundbreaking research uncovered the cancer prevention properties of many dietary compounds, including indole-3-carbinol and diindolylmethane. The modern scientific investigation of I3C as a potential chemopreventive supplement emerged primarily from the 1980s and 1990s, driven by epidemiological observations linking cruciferous vegetable consumption to reduced cancer incidence.
Indole-3-carbinol (I3C) is a major dietary component produced in Brassica vegetables from glucosinolates upon herbivores' attack. I3C is unstable in acidic media and tends to polymerize, rendering its extraction and detection challenging.
In the stomach, I3C molecules undergo acid-catalyzed condensation that generates a number of biologically active I3C oligomers, such as 3,3'-diindolylmethane (DIM) and 5,11-dihydroindolo-[3,2-b]carbazole (ICZ). Indolo[3,2-b]carbazole (ICZ) is formed in aqueous acidic solutions, and the relative yields of trimers versus dimer increase with decreasing pH and with decreasing starting concentration of I3C.
3,3′-Diindolylmethane (DIM) is the principal bioactive metabolite. I3C and its major in vivo product, DIM, are effective cancer chemopreventive agents in pre-clinical models and show promise in clinical trials. The pharmacokinetics/pharmacodynamics of DIM have been studied in both rodents and humans and urinary DIM is a proposed biomarker of dietary intake of cruciferous vegetables. Recent clinical studies at Oregon State University show surprisingly robust metabolism of DIM in vivo with mono- and di-hydroxylation followed by conjugation with sulfate or glucuronic acid. DIM has multiple mechanisms of action, the most well-characterized of which is modulation of aryl hydrocarbon receptor (AHR) signaling.
DIM was the only product detected in plasma samples after non-smoking women subjects (n=24; age between 23 and 58 years) with an elevated risk of breast cancer (by family history) ingested at oral doses of 400, 600, 800, 1000, and 1200 mg of indole-3-carbinol. The maximum plasma concentration (Cmax) of DIM in the women was detected at 1000 mg I3C oral dose. This finding underscores that I3C itself is rapidly converted to DIM and other products in the gastrointestinal tract, and that DIM is the primary circulating form.
AhR activation plays an important role in the chemopreventive effect of indole-3-carbinol and its metabolites. Specifically, AhR upregulates the gene expression of the Phase I enzyme CYP1A1 and the Phase II enzymes glutathione S-transferase and oxidoreductases in prostate and breast cancer cells and in rat liver. These xenobiotic-metabolizing enzymes are involved in inhibiting the activation of chemical carcinogens.
In the cytoplasm, I3C or DIM binds to AhR, which is associated with chaperone proteins. The ligand-bound AhR complex then translocates to the nucleus, where AhR forms a heterodimer with the AhR nuclear translocator (Arnt). The AhR/Arnt complex binds to xenobiotic response elements (XREs) in the promoters of target genes, including the cytochrome P450 (CYP) genes CYP1A1, CYP1B1, and CYP19, resulting in their transcription and subsequent CYP-mediated biotransformation.
CYP1A1 mediates the 2-hydroxylation of estrone, one of the two major competing hydroxylation pathways of estrone metabolism, leading to increased levels of 2-hydroxyestrone. Relative to 16-hydroxyestrone, which is linked to stimulation of estrogen and DNA damage in mammary epithelial cells, 2-hydroxyestrone competes with estradiol for estrogen receptor binding, thereby abrogating the proliferative effect of estradiol.
Via cytochrome P450-dependent pathways, endogenous estrogens such as 17β-estradiol (E2) and estrone (E1) are irreversibly converted to two major metabolites: 2OHE1, which is believed to have anti-estrogenic effects, and 16αOHE1, which has been shown to induce abnormal cell proliferation. I3C and DIM upregulate genes for CYP enzymes that result in increases in 2OHE1 at the expense of 16αOHE1. It has been proposed that a higher ratio of 2OHE1 to 16αOHE1 (2:16 ratio) may be associated with reduced risks of estrogen-sensitive cancers.
Indole-3-carbinol is a negative regulator of ERα signaling in human tumor cells. In addition to altering estrogen metabolism through CYP1A1, indole-3-carbinol and its metabolites also affect ER signaling through two different mechanisms. First, indole-3-carbinol and DIM could bind to and inhibit the activity of ER, which diminishes estradiol-mediated cellular and biochemical effects in estrogen-sensitive cells and tissues. Consequently, indole-3-carbinol could cooperate with tamoxifen to inhibit breast cancer proliferation.
Because several genes that regulate apoptosis, proliferation, and metastasis are regulated by nuclear factor-κB (NF-κB), researchers postulated that indole-3-carbinol mediates its activity through NF-κB modulation. Indole-3-carbinol suppressed constitutive NF-κB activation and activation induced by tumor necrosis factor (TNF), interleukin-1β (IL-1β), phorbol 12-myristate 13-acetate (PMA), lipopolysaccharide (LPS), and cigarette smoke; the suppression was not cell type specific. This activation correlated with the sequential suppression of the IκBα kinase, IκBα phosphorylation, IκBα ubiquitination, IκBα degradation, p65 phosphorylation, p65 nuclear translocation, p65 acetylation, and NF-κB-dependent reporter gene expression.
The NF-κB-regulated gene products cyclin D1, cyclooxygenase-2 (COX-2), matrix metalloproteinase-9 (MMP-9), survivin, inhibitor-of-apoptosis protein-1 (IAP1), IAP2, X chromosome-linked IAP (XIAP), Bcl-2, Bfl-1/A1, TRAF1, and FLIP were all down-regulated by indole-3-carbinol. This down-regulation led to the potentiation of apoptosis induced by cytokines and chemotherapeutic agents. Indole-3-carbinol suppressed constitutive NF-κB activation in mononuclear cells derived from bone marrow of acute myelogenous leukemia patients, and this correlated with inhibition of cell growth.
Indole-3-carbinol and its metabolite DIM target multiple aspects of cancer cell cycle regulation and survival including Akt-NFκB signaling, caspase activation, cyclin-dependent kinase activities, estrogen metabolism, estrogen receptor signaling, endoplasmic reticulum stress, and BRCA gene expression.
Like bortezomib, I3C demonstrates anticarcinogenic properties through multiple mechanisms, including the induction of apoptosis, G1 cell cycle arrest, activation of the endoplasmic reticulum (ER) stress response, and reversal of multi-drug resistance.
The level of p21 transcript, encoding p21 protein involved in the cell cycle, was increased several-fold by I3C compared to its level in cells incubated with estradiol or DDT. The results suggest that the proliferation of MCF-7 cells is accompanied not only by expression of genes encoding cytochromes involved in estrogen metabolism, but also by changes in the expression of other genes including that encoding p21 protein involved in the cell cycle.
I3C administration to rats markedly induces several cytochrome P450s (CYPs), especially CYP1A1 (approximately 25-fold), while at the same time inhibiting the expression of FMO1. The consequence is a marked shift in the metabolic profile of drugs such as nicotine and tamoxifen, which are substrates for both monooxygenases. Such an effect could lead to adverse drug reactions in humans.
I3C and DIM have been found to modulate the expression and activity of biotransformation enzymes that are involved in the metabolism and elimination of many biologically active compounds, including steroid hormones, drugs, carcinogens, and toxins. Microarray gene expression profiling of I3C- or DIM-treated human prostate cancer cells showed that both compounds upregulated the phase I enzyme, CYP1A1, and the phase II enzymes, glutathione S-transferase theta-1 (GSTθ1) and aldo-keto reductase.
Substantial evidence indicates that the antitumor effect of indole-3-carbinol is attributable to its ability to target a plethora of signaling pathways governing apoptosis, cell cycle progression, hormonal homeostasis, DNA repair, angiogenesis, and multiple drug resistance. Moreover, indole-3-carbinol proves to be an effective chemopreventive agent against estrogen-responsive cancers such as breast and cervical cancers, in part, because it functions as a negative regulator of estrogen by inhibiting ERα signaling and altering cytochrome P450-mediated estrogen metabolism.
This broad spectrum of antitumor activities in conjunction with low toxicity underscores the translational value of indole-3-carbinol and its metabolites in cancer prevention and therapy. However, the overall state of human evidence must be characterized carefully.
Epidemiological evidence: Some observational studies have reported significant associations between high intakes of cruciferous vegetables and lower risk of several types of cancer. A meta-analysis of studies carried out over 18 years in Europe revealed an inverse association between weekly consumption of cruciferous vegetables and several common cancers, including colorectal, breast, kidney, and upper digestive tract cancers. Nonetheless, a review of the biomedical research literature found that "evidence of an inverse association between cruciferous vegetable intake and breast or prostate cancer in humans is limited and inconsistent" and "larger randomized controlled trials are needed" to determine whether supplemental I3C confers health benefits.
While epidemiologic studies of cruciferous vegetables and cancer have produced "limited" or "inadequate" data in support of cancer protective effects in studies to date, massive amounts of experimental data as well as recent clinical studies attest to the potential of cruciferous vegetables and their constituents for cancer prevention.
Preclinical studies suggested that anti-estrogenic activities of I3C and DIM might help reduce the risk of hormone-dependent cancers. Although supplementation with I3C and DIM could alter urinary estrogen metabolite profiles in women, the effects of I3C and DIM on breast cancer risk are not known.
I3C supplementation increased urinary 2-hydroxyestrone (2HE1) concentrations in adults at doses of 300 to 400 mg/day. In premenopausal women, a supplement containing I3C and 7-hydroxymatairesinol, a dietary ingredient, increased the urinary 2:16-hydroxyestrone ratio, a known biomarker for the reduction of breast cancer risk.
Two Phase I clinical trials of I3C with promising results have been reported, featuring patients with recurrent respiratory papillomatosis or cervical intraepithelial neoplasia. I3C has also been the subject of a breast cancer prevention dose-finding pilot study and has been shown to act cooperatively with tamoxifen in vitro.
More recently, an RCT of a diindolylmethane formulation (DIM, an active I3C metabolite) in breast cancer patients on tamoxifen suggests it encourages beneficial changes in estrogen metabolism and circulating sex hormone-binding globulin levels.
Evidence strength: Evidence for a direct effect on breast cancer prevention or treatment in humans is preliminary. Mechanistic and biomarker data are supportive, but large, adequately powered RCTs confirming clinical outcomes have not been reported as of the available literature. The National Institutes of Health (NIH) has reviewed indole-3-carbinol as a possible cancer preventive agent and is now sponsoring clinical research for breast cancer prevention.
Cervical dysplasia and HPV-associated cervical disease represent the area where the strongest human trial evidence has been assembled for I3C.
A twelve-week, placebo-controlled trial of thirty women with stage two or three cervical dysplasia found that treatment with I3C at a daily dose of 200 or 400 mg significantly improved the rate at which the cervix spontaneously returned to normal.
I3C doses of 200 mg/day or 400 mg/day improved the regression of cervical intraepithelial neoplasia (CIN) in this preliminary clinical trial.
Data from early phase clinical trials suggested that I3C is effective against precancerous cervical dysplasia and vulvar intraepithelial neoplasia.
Evidence strength: Preliminary clinical trial data are encouraging; however, the trials were small, short-term, and limited to early-phase designs. Limited evidence from preliminary trials suggested that I3C supplementation may help treat conditions related to human papilloma virus (HPV) infection, such as cervical/vulvar intraepithelial neoplasias and recurrent respiratory papillomatosis. However, randomized controlled trials are needed to determine whether I3C supplementation is beneficial.
Previous studies have demonstrated a potential benefit of I3C in the treatment of high-risk breast cancer, vulvar intraepithelial neoplasia, and recurrent respiratory papillomatosis, while clinical trials of I3C are ongoing in cervical and prostate cancer. A randomized Phase II trial of I3C in the treatment of vulvar intraepithelial neoplasia was published in the International Journal of Gynecological Cancer (2006), with the investigators reporting some preliminary benefit, though the evidence base remains limited to small trials.
Evidence strength: Preliminary; Phase II trial data with limited sample sizes. Larger confirmatory trials are needed.
A clinical study reported results using I3C for the treatment of recurrent respiratory papillomatosis (RRP). I3C is abundant in cruciferous vegetables and has been shown to decrease papillomatous growth in cell cultures and to be effective in an animal model of RRP. This was a prospective, open-label study design. Patients with RRP were enrolled from September 1996 to August 2001 and treated with I3C (adult dose of 200 mg orally twice daily). All patients underwent complete surgical removal and then started I3C. Further surgery was performed on an as-needed basis. Patients were categorized as having a complete, partial, or no response to I3C.
Thirty-three patients treated with I3C were available for long-term follow-up (mean = 4.8 years), whereas 12 patients were lost to follow-up. Eleven (33%) patients experienced remission of papillomatous growth and did not require surgery while on I3C.
There is some evidence that long-term use of indole-3-carbinol might reduce tumor (papilloma) growth in patients with recurrent respiratory papillomatosis.
Evidence strength: Open-label, uncontrolled prospective design with no placebo comparator; 33% remission rate in a relatively small cohort. The absence of randomized controlled data limits definitive conclusions.
Epidemiological evidence has demonstrated a reduced risk of prostate cancer associated with cruciferous vegetable intake. Follow-up studies have attributed this protective activity to the metabolic products of glucosinolates, a class of secondary metabolites produced by crucifers.
Although prostate cancer has been inversely associated with high consumption of cruciferous vegetables in case-control studies, results of a prospective study did not confirm the protective effects. In vitro and animal model data show I3C induces apoptosis in prostate cancer cell lines and inhibits Akt signaling, but robust clinical trial data specific to I3C are lacking. DIM — the primary I3C metabolite — has increased estrogen metabolism, decreased androgen-specific antigen, up-regulated BRCA1 expression, and increased androgen hormone-binding globulin in clinical studies.
Evidence strength: Epidemiological associations are inconsistent. Preclinical data are substantial. Direct human RCT evidence for I3C or DIM in prostate cancer outcomes is insufficient.
Studies have demonstrated that the consumption of cruciferous vegetables is associated with a reduced risk of several cancers, including lung, prostate, bladder, and gastric cancers. In specific animal experiments, controlled studies have been performed on rats, mice, and rainbow trout, introducing various controlled levels of carcinogens and levels of indole-3-carbinol into their daily diet. Results showed dose-related decreases in tumor susceptibility due to indole-3-carbinol, inferred by decreases in aflatoxin–DNA binding.
Evidence strength: Animal and in vitro data are substantial. Human clinical trial data specific to I3C for colorectal or other cancers are absent or minimal.
Animal studies of I3C's impact on SLE showed positive potential results in slowing SLE's progression into kidney disease, resulting in longer life spans. However, a small human trial did not replicate these results.
Evidence strength: Animal-model data only with positive signal; small human trial non-replicating. Evidence is insufficient to support clinical use for SLE.
Research into cardiovascular and anti-inflammatory properties of I3C is at an early and predominantly preclinical stage. In animal studies, indole-3-carbinol reduced oxidative-inflammatory markers and systolic blood pressure in spontaneously hypertensive rats. Indole-3-carbinol also reduced reperfusion arrhythmias from 8/10 in spontaneously hypertensive rats to 0/10. The investigators concluded that indole-3-carbinol reduces the inflammatory-oxidative-proarrhythmic process of hypertension.
Evidence strength: Animal models only; no human clinical data. The antihypertensive and anti-arrhythmic findings require independent confirmation and human study before clinical relevance can be established.
I3C is present at a relatively high level in most cruciferous vegetables such as cabbage, broccoli, and collard greens. Functional studies have shown that I3C supplementation can produce numerous pharmacological activities, such as anti-oxidative stress and anti-carcinogenesis. I3C supplementation can also suppress the production of pro-inflammatory cytokines in different animal models of disease.
The immune-modulatory effects of I3C are complex and context-dependent. In a study using nonobese diabetic (NOD) mice, I3C — which is found in cruciferous vegetables and will regulate the aryl hydrocarbon receptor (AhR) via metabolites produced during digestion — led to strong AhR activation in the small intestine but minimal systemic AhR activity. In the absence of this systemic response, the dietary intervention led to exacerbated insulitis. This finding underlines that I3C's immune effects can be unpredictable and tissue-compartment dependent.
Evidence strength: Primarily preclinical. The bidirectional and context-dependent nature of immune modulation requires further human study before clinical guidance can be offered.
The following dosages are reported as they appear in primary sources; they do not represent dosing recommendations:
I3C is generally well tolerated when taken orally, but it is unclear if I3C supplementation can benefit humans due to its mixed effects in preliminary studies and its ability to induce cytochrome P450 enzymes, which may cause interactions with several medications.
Indole-3-carbinol is likely safe for most people when used in amounts typically found in the diet. It seems to be safe for most people when used in medicinal amounts under proper medical supervision. It can cause side effects such as skin rashes and small increases in liver enzymes. In very high doses, indole-3-carbinol can cause balance problems, tremor, and nausea.
Some medications are changed and broken down by the liver. Indole-3-carbinol might increase how quickly the liver breaks down some medications. Taking indole-3-carbinol along with some medications that are changed by the liver can decrease the effectiveness of some medications. Some of these medications include clozapine (Clozaril), cyclobenzaprine (Flexeril), fluvoxamine (Luvox), haloperidol (Haldol), imipramine (Tofranil), mexiletine (Mexitil), olanzapine (Zyprexa), pentazocine (Talwin), propranolol (Inderal), tacrine (Cognex), theophylline, zileuton (Zyflo), and zolmitriptan (Zomig).
Indole-3-carbinol might slow blood clotting. Taking indole-3-carbinol along with medications that also slow blood clotting might increase the risk of bruising and bleeding.
A critical and widely noted safety consideration is that I3C's relationship to cancer is not uniformly protective. Some concern has been raised related to the long-term use of I3C, as in some models chronic dietary post-initiation exposures promote cancers. Animal studies have documented both cancer-inhibiting and cancer-promoting effects depending on the timing of administration (before versus after tumor initiation), species, dose, and tissue type. For example, studies in rats have observed enhancement of liver and thyroid gland neoplastic development, and promotion of endometrial adenocarcinoma development, under specific experimental conditions. This bidirectional carcinogenesis profile — anticarcinogenic when given prior to initiation, potentially promoting when given after initiation — is consistently noted in toxicological reviews.
Indole-3-carbinol exhibited the potential to be a reproductive toxicant in female rats based on a significantly increased probability of extended diestrus at high doses in the NTP gavage studies. This finding has not been confirmed in humans, and the doses employed in those animal studies (given by gavage in corn oil) substantially exceed typical human supplement doses.
Indole-3-carbinol was nominated by the National Cancer Institute for toxicity and carcinogenicity testing because of its occurrence in natural products and for its potential use as a breast cancer chemopreventive agent. The comprehensive NTP Technical Report 584 (2017) involved both three-month and two-year gavage studies in multiple rodent strains, yielding data on organ weight changes, enzyme induction, histopathological changes, and carcinogenicity signals at high doses.
The mechanism by which indole-3-carbinol inhibits tumorigenesis remains inconclusive, which, in part, might be attributable to its metabolic instability and complicated pharmacological properties. The intrinsic instability of indole-3-carbinol in acidic milieu arises from the vinyl hemiaminal moiety of the indole ring. The wide range of oligomeric condensation products generated in the stomach means that the precise active compound profile varies between individuals, doses, and formulations, making toxicological and efficacy predictions challenging.
Health conditions that Indole-3-carbinol may help support.
Indole-3-Carbinol (I3C) is a glucosinolate hydrolysis product from cruciferous vegetables and the dietary precursor to DIM (diindolylmethane). I3C modulates estrogen metabolism and aromatase activity, reducing the testosterone-competing estrogen burden in aging men. It is listed among the most prevalent individual components in testosterone booster/andropause supplement formulations.
I3C upregulates phase II detoxification and antioxidant enzymes including glutathione S-transferase (GST) and heme oxygenase-1 via AhR and Nrf2-related pathways. A human study in 52 participants demonstrated a 69% rise in GST activity with I3C supplementation. It also reduces free radical formation by inhibiting CYP-dependent estrogen metabolic activation that would otherwise generate reactive intermediates.
I3C has been most studied in the context of systemic lupus erythematosus (SLE), both in lupus-prone mouse models and in human ex vivo and pilot clinical studies. In (NZB×NZW)F1 lupus mice, I3C significantly prolonged survival and reduced autoantibodies by inducing tandem B- and T-cell differentiation blockades. Human ex vivo work demonstrated AhR-mediated immunoregulatory effects on SLE macrophages, and a pilot NIH-sponsored clinical trial investigated I3C in women with SLE.
Indole-3-carbinol (I3C), derived from cruciferous vegetables, has been studied in a placebo-controlled trial at 200–400 mg/day, showing improved regression of cervical intraepithelial neoplasia (CIN). It modulates estrogen metabolism toward less oncogenic metabolites and exerts anti-estrogenic activity in cervical cells. Evidence is promising but limited by small trial size.
I3C suppresses the master inflammatory transcription factor NF-κB and downstream cytokines including IL-1β, IL-6, and TNF-α in multiple preclinical models. It also inhibits cyclooxygenase-2 and inducible nitric oxide synthase expression. Human ex vivo work in SLE patients demonstrates modulation of macrophage inflammatory cytokine balance. Direct large-scale human RCTs targeting chronic inflammation as a primary endpoint are still lacking.
Indole-3-carbinol (I3C) is the direct dietary precursor to DIM, found in cruciferous vegetables. It promotes favorable estrogen metabolism, inhibits estrogen receptor signaling, and exhibits anti-proliferative effects on endometrial cells. Its relevance to endometriosis derives from anti-estrogenic and anti-proliferative mechanisms; clinical RCT data specific to endometriosis are not yet published.
Indole-3-carbinol (I3C), derived from glucobrassicin in cruciferous vegetables, is among the most potent natural inducers of phase II detoxification enzymes. These enzymes (glutathione S-transferases, quinone reductase, NQO1) are critical for metabolizing and eliminating environmental carcinogens, xenobiotics, and chemical pollutants from the body.
Indole-3-Carbinol (I3C) is a glucosinolate breakdown product from cruciferous vegetables that promotes 2-hydroxylation of estrogens via CYP1A induction, reducing the ratio of genotoxic estrogen metabolites. Epidemiological, laboratory, and animal studies support its role as a negative regulator of estrogen-driven cell proliferation. It is the precursor to DIM and is used clinically for estrogen balance and cervical dysplasia.
Indole-3-Carbinol (I3C) is a phytochemical from cruciferous vegetables that induces estrogen 2-hydroxylation through cytochrome P450 enzymes, shifting metabolite profiles toward the less estrogenic pathway. A randomized trial in 60 women demonstrated 400 mg/day for 3 months significantly raised the urinary 2-OH-estrone:estriol ratio. It acts as a negative regulator of estrogen receptor-alpha signaling and is a precursor to DIM.
Indole-3-carbinol (I3C) from cruciferous vegetables induces hepatic phase I (CYP1A2) and phase II (GST, UGT) detoxification enzymes, promoting favorable metabolism and excretion of estrogens, carcinogens, and xenobiotics. It is well-documented in the literature on dietary support of hepatic detoxification biotransformation pathways. I3C and its dimer DIM are among the best-studied cruciferous phytochemicals for liver detox enzyme induction.
I3C has been studied clinically as an adjunct treatment for recurrent respiratory papillomatosis (RRP), an HPV-driven condition causing papillomas of the larynx and airway. Phase I and prospective open-label clinical studies in 18–45 patients showed papilloma growth cessation or reduction in roughly one-third of treated patients. Preclinical studies also demonstrate inhibition of tobacco smoke carcinogen-induced lung adenocarcinoma in animal models.
I3C has direct human clinical evidence for reducing HPV-driven papillomas (polyp-like growths) of the respiratory tract. In RRP trials, approximately one-third of patients achieved full papilloma remission on I3C. For cervical polyp-like lesions (CIN II-III), a placebo-controlled trial showed complete regression in approximately 50% of I3C-treated patients versus 0% on placebo. Colonic adenoma/polyp evidence is preclinical and conflicting.
Indole-3-carbinol (I3C), derived from hydrolysis of glucobrassicin in cruciferous vegetables, inhibits prostate cancer cell growth in vitro and in vivo, induces G1 cell-cycle arrest, and modulates androgen-dependent pathways. Its active dimer DIM shows early-phase clinical evidence of slowing prostate cancer progression. Epidemiological data link cruciferous vegetable intake to decreased prostate cancer risk.
Indole-3-carbinol (I3C) is the dietary precursor to DIM (diindolylmethane) found in cruciferous vegetables. It modulates estrogen metabolism toward less active metabolites, potentially supporting the testosterone-to-estrogen ratio in men. It is listed alongside DIM in testosterone-supplement reviews as a relevant ingredient for hormone balance.
Indole-3-Carbinol (I3C), found in cruciferous vegetables, has demonstrated anti-uterine fibroid activity in preclinical studies, inhibiting extracellular matrix expression in primary human uterine leiomyoma cells and modulating estrogen metabolism to favor less potent estrogen metabolites protective of uterine tissue.
Body systems that Indole-3-carbinol may help support.
Go back